An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen.
about
Expression of FOXA1 and GATA-3 in breast cancer: the prognostic significance in hormone receptor-negative tumoursLong chain fatty Acyl-CoA synthetase 4 is a biomarker for and mediator of hormone resistance in human breast cancerRole of the androgen receptor in breast cancer and preclinical analysis of enzalutamideProlactin-induced protein mediates cell invasion and regulates integrin signaling in estrogen receptor-negative breast cancerDART: Denoising Algorithm based on Relevance network Topology improves molecular pathway activity inferenceApolipoprotein D: an overview of its role in aging and age-related diseasesMigrastatin analogues target fascin to block tumour metastasisTargeting androgen receptor in estrogen receptor-negative breast cancerPhase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast CancerPioneer transcription factors: establishing competence for gene expressionMechanisms of oestrogen receptor (ER) gene regulation in breast cancerThe fate of chemoresistance in triple negative breast cancer (TNBC)Triple negative breast cancer: looking for the missing link between biology and treatmentsTargeting the androgen receptor in prostate and breast cancer: several new agents in developmentBiological network-driven gene selection identifies a stromal immune module as a key determinant of triple-negative breast carcinoma prognosis.Androgen Receptor: A Complex Therapeutic Target for Breast CancerRunx2 controls a feed-forward loop between androgen and prolactin-induced protein (PIP) in stimulating T47D cell proliferationGene expression meta-analysis supports existence of molecular apocrine breast cancer with a role for androgen receptor and implies interactions with ErbB familyProgesterone receptor-B enhances estrogen responsiveness of breast cancer cells via scaffolding PELP1- and estrogen receptor-containing transcription complexesmRNA profiling reveals determinants of trastuzumab efficiency in HER2-positive breast cancerThe Hippo kinases LATS1 and 2 control human breast cell fate via crosstalk with ERαIdentification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapiesNuclear localisation of LASP-1 correlates with poor long-term survival in female breast cancer.Global gene expression analysis identifies PDEF transcriptional networks regulating cell migration during cancer progressionBreast cancer classification and prognostication through diverse systems along with recent emerging findings in this respect; the dawn of new perspectives in the clinical applications.Estimating DNA methylation levels by joint modeling of multiple methylation profiles from microarray dataA gene transcription signature associated with hormone independence in a subset of both breast and prostate cancersImportance of Breast Cancer Subtype in the Development of Androgen Receptor Directed Therapy.Enumerating the gene sets in breast cancer, a "direct" alternative to hierarchical clustering.Molecular apocrine breast cancers are aggressive estrogen receptor negative tumors overexpressing either HER2 or GCDFP15.Expression of Long-chain Fatty Acyl-CoA Synthetase 4 in Breast and Prostate Cancers Is Associated with Sex Steroid Hormone Receptor Negativity.Minimising immunohistochemical false negative ER classification using a complementary 23 gene expression signature of ER statusGlobal analysis of ZNF217 chromatin occupancy in the breast cancer cell genome reveals an association with ERalpha.Prolactin-induced protein is required for cell cycle progression in breast cancer.Reciprocal regulation of ZEB1 and AR in triple negative breast cancer cells.Prevalence and predictors of androgen receptor and programmed death-ligand 1 in BRCA1-associated and sporadic triple-negative breast cancer.Consistent metagenes from cancer expression profiles yield agent specific predictors of chemotherapy response.Identification of a novel luminal molecular subtype of breast cancer.Gross cystic disease fluid protein 15 (GCDFP-15) expression in breast cancer subtypes18F-FDG PET of locally invasive breast cancer and association of estrogen receptor status with standardized uptake value: microarray and immunohistochemical analysis
P2860
Q21030553-1581205B-6DF1-4A8C-B49A-5D421D22FA3DQ21132473-D88D15C2-6313-4255-A1BE-3DB2C7B7F188Q21195191-830BA7E5-20CC-4152-AB01-8547C8431FF0Q21195199-D1675255-B8CF-429A-9E18-348316CE67AEQ21284334-B37E10FD-9CE1-47C5-99FC-3E5AF91C0F5AQ24292893-719FAF6F-414B-4F73-B517-87346B365F3DQ24306715-A6342116-9C3D-424A-ABE9-55154D7DBF41Q24312457-45D4F9C6-6B81-4E50-A873-275C8F4EB67EQ24563045-1608CBD9-080C-4F5B-82A3-42205808A746Q24625373-F92DEFA2-41EA-4FAF-927D-3C7F439F339FQ26765380-519952E3-7157-48B3-A076-BAAA27C6879FQ26775232-D96663BE-0CBF-4184-86F1-93377B546765Q26783122-61E4ADE6-B69F-4107-B895-CA5757D44220Q27009424-4178AD68-76A6-41D1-A9FA-88FFBA029053Q27311085-23B4558F-9E0D-4B10-9E6F-690B7CE6619AQ28075188-2A91EC25-88C3-4E48-934E-25EF6C8CD958Q28244711-7B1EBBF2-DA66-4E7C-9390-6F4D8DEF874AQ28258227-832EF3BE-BC73-4713-804D-CFF1ED01A0FDQ28306753-7A910C12-0DD9-4E7C-9125-CA8C76DCEB6CQ28543647-C4DA3C90-4430-48D1-9495-BE293266BA64Q28596581-F834F8A3-DF87-4582-83B4-9804D5073E22Q29617680-887B037C-5A09-4948-93CC-5ED3F6B34438Q30156863-AF23BABC-B1D5-430B-A566-92FB92FBE4DBQ30157655-A8BB7637-DE3F-4BA2-B6FB-07AEC449577EQ30245184-2A06EA71-C8D7-4A06-AE6F-3BC9735ADCCFQ31001241-F057A8D8-D1E4-462C-B7F2-14360EE94799Q33289245-51FF5F7A-F146-44C3-A306-C392C065A57CQ33632582-43B4D55D-ABF5-4204-A61E-768CC3D4312DQ33669571-B21D18AE-1938-40FA-92AC-40752ED5DABFQ33739841-94AE0579-9C18-44BF-9BB3-7DA7B41D00BFQ33760590-C9F163E4-212A-4098-9E25-3772351ECEF9Q33769803-11D736FE-4B6B-400F-8ED2-551019A05721Q33848844-DFEFD21D-9897-46E6-AF75-8E70CA5F70D8Q33891258-F6893959-9A89-42B9-9DA1-E9A5FA26F855Q33909645-DC672CBB-A370-4D41-A1BA-767F37F1B5AFQ33915040-ED00DCC9-607B-495F-9E0E-A199D2EC6361Q33974305-9BF6C76B-941C-4743-A502-EE241C88BE77Q33975444-51903B6B-2F06-4171-9460-33F41D9DA8FDQ34006749-DDBAE075-CD97-4D0A-8075-74BC54C7D435Q34078191-85CFCA68-B685-4C23-8867-D2857432E044
P2860
An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
An estrogen receptor-negative ...... gram and response to androgen.
@en
type
label
An estrogen receptor-negative ...... gram and response to androgen.
@en
prefLabel
An estrogen receptor-negative ...... gram and response to androgen.
@en
P2093
P356
P1433
P1476
An estrogen receptor-negative ...... gram and response to androgen.
@en
P2093
P2888
P304
P356
10.1038/SJ.ONC.1209415
P407
P577
2006-02-20T00:00:00Z
P5875
P6179
1039718069